Mpox primer for clinicians: what makes the difference in 2024?

By sjmartinez • January 16, 2025

Abdel-Rahman SM, Bayıcı BZ, Keske Ş, Kuşkucu M, Özsürekçi Y, Rimoin AW, Rodriguez-Morales AJ, Ergönül Ö. Mpox primer for clinicians: what makes the difference in 2024? Curr Opin Infect Dis. 2025 Jan 16. doi: 10.1097/QCO.0000000000001091. Epub ahead of print. PMID: 39813011.

Tags: Infectious Diseases, Publications

In Silico Design of a Multiepitope Vaccine Against Intestinal Pathogenic Escherichia coli Based on the 2011 German O104:H4 Outbreak Strain Using Reverse Vaccinology and an Immunoinformatic Approach

Youssef EG, Elnesr K, Hanora A. In Silico Design of a Multiepitope Vaccine Against Intestinal Pathogenic Escherichia coli Based on the 2011 German O104:H4 Outbreak Strain Using[...]

Cabotegravir pharmacokinetics in Asians with and without HIV

Han K, Abulfathi AA, Mehta RS, Nand RA, Marzinke MA, Landovitz RJ, D'Amico RD, Rinehart AR, Spreen WR, Ford SL. Cabotegravir pharmacokinetics in Asians with[...]

Depression improves the predictive accuracy of the VACS Index 2.0 for all-cause mortality among sexual minority men living with HIV in the Multicenter AIDS Cohort Study

Qian Y, Comulada WS, Hidalgo MA, Lee SJ, Friedman MR, Palella FJ, Plankey MW, D'Souza G, Detels R, Mimiaga MJ. Depression improves the predictive accuracy[...]